PHP
SLN

Parkman Healthcare Partners’s Silence Therapeutics SLN Stock Holding History

Parkman Healthcare Partners’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-401,746
Closed -$1.13M – 101
2025
Q1 		$1.13M Sell
401,746
-89,334
-18% -$436K 0.13% 83
2024
Q4 		$3.38M Sell
491,080
-6,790
-1% -$87.6K 0.45% 57
2024
Q3 		$9.05M Buy
497,870
+208,029
+72% +$3.87M 1.16% 32
2024
Q2 		$5.51M Buy
289,841
+45,370
+19% +$965K 0.74% 47
2024
Q1 		$5.28M Buy
244,471
+11,529
+5% +$251K 0.65% 50
2023
Q4 		$4.05M Buy
232,942
+40,063
+21% +$450K 0.57% 56
2023
Q3 		$1.89M Buy
192,879
+7,801
+4% +$57.6K 0.35% 77
2023
Q2 		$1.02M Buy
185,078
+26,304
+17% +$159K 0.18% 86
2023
Q1 		$984K Buy
158,774
+23,932
+18% +$282K 0.21% 72
2022
Q4 		$2.06M Buy
134,842
+7,384
+6% +$96.8K 0.55% 57
2022
Q3 		$1.28M Buy
127,458
+101,208
+386% +$1.07M 0.36% 69
2022
Q2 		$311K Buy
+26,250
New +$319K 0.11% 75

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Parkman Healthcare Partners's SLN Position: Q2 2025 in Review

Parkman Healthcare Partners sold out of Silence Therapeutics (SLN) in Q2 2025, closing a stake of 401,746 shares — an estimated $1.13M sold.

Parkman Healthcare Partners first reported a position in SLN in Q2 2022 and held it in 12 quarters. The position peaked at $9.05M in Q3 2024. 55 funds tracked by Wall St. Rank hold SLN as of Q2 2025.

  • Parkman Healthcare Partners reported no remaining Silence Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Parkman Healthcare Partners sold 401,746 Silence Therapeutics shares in Q2 2025, an estimated $1.13M.
  • Parkman Healthcare Partners first reported a position in Silence Therapeutics in Q2 2022 and held it in 12 quarters.
  • Parkman Healthcare Partners's Silence Therapeutics position peaked at $9.05M in Q3 2024.
  • 55 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2025.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.